Syncom Formulations India Ltd vs Zenith Drugs Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 05, 2026

Key Highlights

The Latest Trading Price of Syncom Formulations (India) Ltd is ₹ 14.06 as of 05 May 15:30 . The P/E Ratio of Syncom Formulations (India) Ltd changed from 46.2 on March 2022 to 31 on March 2025 . This represents a CAGR of -9.49% over 4 yearsThe P/E Ratio of Zenith Drugs Ltd changed from 11.2 on March 2024 to 0 on March 2025 . This represents a CAGR of -100.00% over 2 years The Market Cap of Syncom Formulations (India) Ltd changed from ₹ 916.79 crore on March 2022 to ₹ 1546 crore on March 2025 . This represents a CAGR of 13.96% over 4 yearsThe Market Cap of Zenith Drugs Ltd changed from ₹ 107.52 crore on March 2024 to ₹ 0 crore on March 2025 . This represents a CAGR of -100.00% over 2 years The revenue of Syncom Formulations (India) Ltd for the Dec '25 is ₹ 120.64 crore as compare to the Sep '25 revenue of ₹ 126.97 crore. This represent the decline of -4.99% The revenue of Zenith Drugs Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 revenue of ₹ 0 crore. This represent the decline of 0% The ebitda of Syncom Formulations (India) Ltd for the Dec '25 is ₹ 26.71 crore as compare to the Sep '25 ebitda of ₹ 23.65 crore. This represent the growth of 12.94% The ebitda of Zenith Drugs Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 ebitda of ₹ 0 crore. This represent the decline of 0% The net profit of Syncom Formulations (India) Ltd changed from ₹ 7.63 crore to ₹ 18.91 crore over 7 quarters. This represents a CAGR of 67.97% The net profit of Zenith Drugs Ltd changed from ₹ 0 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of 0.0% The Dividend Payout of Syncom Formulations (India) Ltd changed from 13.07 % on March 2022 to 0 % on March 2025 . This represents a CAGR of -100.00% over 4 yearsThe Dividend Payout of Zenith Drugs Ltd changed from 8.99 % on March 2024 to 0 % on March 2025 . This represents a CAGR of -100.00% over 2 years .

About Syncom Formulations (India) Ltd

Incorporated as a private limited Company in 1988, Syncom Formulations (India) Limited was converted into a public limited Company in June, 1992.
The Company in the Indian Pharmaceutical Industry represents synergistic combination of commitment and consistency.
Syncom possesses the manufacturing strength in its own manufacturing set-up at Pithampur, Madhya Pradesh. Established in 1988, Syncom plant is geared up with latest production machineries and maintains high quality standards.
Currently, the Company manufactures and markets more than 200 pharmaceutical formulations products in various dosage forms like Tablets, Capsules, Liquids Orals, Liquid Vials and Ampoule Injections & Dry Vial injections, Dry Syrups, Ointments and Inhalers. The company set up a manufacturing facility at Palghar, Thane to produce pharmaceutical formulations.

About Zenith Drugs Ltd

Zenith Drugs Ltd was originally incorporated on November 15, 2000 as a Private Limited Company in the name of 'Zenith Drugs Private Limited' issued by the Registrar of Companies, in the State of Madhya Pradesh, Gwalior.
Subsequently, Company was converted into Public Limited and consequently, the name of Company was changed to Zenith Drugs Limited' pursuance to issuance of a Fresh Certificate of Incorporation on September 13, 2023 by the Registrar of Companies, Gwalior. Zenith are a reputable pharmaceutical manufacturing and trading unit based out from Indore.
With a diverse portfolio of formulations, the Company is specialized in manufacturing affordable and high quality medicines to meet the needs of patients.
The Company is mainly engaged in the business of manufacturing and Trading of Medicines.

FAQs for the comparison of Syncom Formulations (India) Ltd and Zenith Drugs Ltd

Which company has a larger market capitalization, Syncom Formulations (India) Ltd or Zenith Drugs Ltd?

Market cap of Syncom Formulations (India) Ltd is 1,321 Cr while Market cap of Zenith Drugs Ltd is 77 Cr

What are the key factors driving the stock performance of Syncom Formulations (India) Ltd and Zenith Drugs Ltd?

The stock performance of Syncom Formulations (India) Ltd and Zenith Drugs Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Syncom Formulations (India) Ltd and Zenith Drugs Ltd?

As of May 5, 2026, the Syncom Formulations (India) Ltd stock price is INR ₹14.06. On the other hand, Zenith Drugs Ltd stock price is INR ₹45.35.

How do dividend payouts of Syncom Formulations (India) Ltd and Zenith Drugs Ltd compare?

To compare the dividend payouts of Syncom Formulations (India) Ltd and Zenith Drugs Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.